Abstract In March 2013, the Acromegaly Consensus Group met to revise and update
guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled …

Context: Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety
surveillance study of long-term treatment of acromegaly with pegvisomant. Objective: The …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

AACE= American Association of Clinical Endocrinologists; BEL=“best evidence” level;
BMD= bone mineral density; CPAP= continuous positive airway pressure; CPG= clinical …

Objective To report the final long-term safety and efficacy analyses of patients with
acromegaly treated with pegvisomant from the ACROSTUDY. Design Global (15 countries) …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

Background: Treatment for acromegaly patients with long-acting somatotropin release-
inhibiting factor (LA-SRIF) often does not result in complete normalization of IGF-1. Addition …

The currently available somatostatin receptor ligands (SRLs) and growth hormone (GH)
antagonists are used to control levels of GH and insulin-like growth factor 1 (IGF-1) in …

Background In 2007, we published an opinion document to review the role of pegvisomant
(PEG) in the treatment of acromegaly. Since then, new evidence emerged on the …

Physicians and patients have long been aware of skin lesions at the sites of insulin
injections, referred to as lipodystrophy that can present as lipoatrophy (LA) or …